Skip to content

Dr. Eline Daelemans

Active
Private limited company·Activiteiten van huisartspraktijken· 4 yrs active
Grote Steenweg 17 ·9930 Lievegem, Belgium
KBO/BCE: BE 0787.421.254
Watch Print / PDF
Age4 yrs

Summary

Conclusion

the dossier summarised in one paragraph

The computed 12-month bankruptcy probability of Dr. Eline Daelemans is 0.2% (very low). The 2024 annual accounts show equity of €370k and a net result of €162k. Equity is growing by ~72.6% per year across the filed fiscal years. Its solvency ranks better than 95% of 6588 sector peers (fiscal year 2024). The company has been active since 2022 and the Belgian State Gazette contains no insolvency or warning signals.

Based on the State Gazette, CBE and 3 annual accounts.

Signals

3 signals · with evidence
Strong solvency vs sector
Solvency is in the sector's strongest quartile: better than 95% of 6588 peers (2024). A comfortable equity buffer.
View the sector comparison
Consistently profitable
Positive net result in the two most recent financial years (2023 and 2024).
View the result trend
Growing equity
Equity grew over 2022-2024. Profits are largely retained rather than distributed.
View the equity trend

Signals are derived from the filed annual accounts and the sector comparison. No composite score: each signal is separately verifiable at the source.

Filing behaviour

From the deposit records, complete market-wide
Deadline passed, not yet counted as missing
The deadline for the year that closed on 31-12-2025 passed on 31-07-2026, 23 days ago. Our copy of the deposit register trails the National Bank (measured: median 14 days, p99 45 days), so we only call this filing missing from 45 days past the deadline.
Latest accounts filed on time
The financial year that closed on 31-12-2024 was due by 31-07-2025 and was filed on 23-06-2025, 38 days ahead of the deadline. This speaks to administrative punctuality and says nothing about the financial position.
How we compute the deadline
The year end is derived from 3 filed financial years, each closing on 31-12. The statutory deadline is seven months after the close of the financial year (art. 3:10 par. 1 CAC, art. 3:47 par. 7 for ASBL and foundations). Applied to the financial year that closed on 31-12-2024, that is 31-07-2025.
Deadline per financial year
Year closed Due by Filed Variance Reference
31-12-2025 31-07-2026 nothing on record not filed -
31-12-2024 31-07-2025 23-06-2025 38 d early 2025-00167630
31-12-2023 31-07-2024 05-07-2024 26 d early 2024-00211199
31-12-2022 31-07-2023 22-08-2023 22 d late 2023-00339772

Source: the National Bank's deposit records. Those records are complete, including for years whose figures we have not read yet. Filing late covers nearly half the market and is therefore not scored; only not filing, being more than 90 days late and breaking a punctual record carry weight.

Trust signals

2 signals
More than 3 years active
Founded in 2022, past the statistically most fragile first 3 years.
No legal incidents
No bankruptcy, reorganisation or interim measure in the Belgisch Staatsblad, and the KBO register records a normal legal situation.

Administrative Flags

No strikeouts found in the KBO publications we processed. That series starts in 2021 and has gaps, so this is not a confirmation that there is nothing.

Bankruptcy probability (12 mo)

Checked model v1 · free for everyone
0.2% Very low
0%0,5%1,5%4%10%≥25%
Lower-failure-rate sector Young company +Annual accounts: healthy financial profile

Statistical estimate based on public sources, not credit advice nor a finding of fact. How do we compute this?

Financials

TurnoverNot published (abbreviated filing)
EBIT marginNot published (abbreviated filing)
Net result€162k+15.6%
Working capital€203k+225.7%

Annual accounts & ratios

Source: NBB · 2024
Annual accounts filed on 23-06-2025 with the NBB · fiscal year 2024 · micro
€0€100k€200kOperating result 2022: €82k€82kNet result 2022: €65k€65kOperating result 2023: €179k€179kNet result 2023: €140k€140kOperating result 2024: €207k€207kNet result 2024: €162k€162k202220232024
Operating resultNet result
Trajectory (indicative)
Projection over 3 fiscal years from the filed annual accounts, not a forecast, the extended trend.
growing Equity: growth of ~72.6%/year over 3 fiscal years, indicative, assuming unchanged policy.
€0€200k€400k€600k€800k2025: €520k (€491k - €550k)2026: €671k (€641k - €701k)2027: €822k (€792k - €851k)2022: €68k2023: €207k2024: €370k202220232024202520262027
Solid line = filed figures · dashed = extended trend · area = indicative range.
How do we compute this?

The trend is a robust median of all pairwise slopes between fiscal years (Theil-Sen), so a single odd year cannot hijack the line. For strictly positive series we also fit a log variant (compound annual growth) and keep whichever describes the figures best.

The area around the projection is 1.8 × the median absolute deviation from the trend, widening each year ahead (×1 / ×1.6 / ×2.2), with a minimum of 8% of the last value. It is an indicative range, not a statistical confidence interval.

A series whose deviations exceed 35% of its level is too volatile: we then deliberately show no projection. Every projection assumes unchanged policy and is blind to non-public information (order book, contracts, funding rounds).

Sector comparison
Fiscal year 2024 · NACE 86, Human health · compared within the same schema type (micro schema)
Metric This company Sector median Position in the sector
Solvency 100.0% 66.7%
better than 95% of 6588 sector peers
Net result €162k €46k
better than 90% of 6582 sector peers
Equity €370k €79k
better than 92% of 6588 sector peers
Gross operating margin €209k €78k
better than 86% of 6590 sector peers
Total assets €370k €154k
better than 80% of 6591 sector peers
Median and position computed from NBB annual accounts filed by sector peers; own figures from the latest filed accounts.
Sector position over time
Percentile per fiscal year versus peers that filed figures, computed year by year (a year without enough peers is absent).
Solvency P95
2022: P79 · n=36882023: P94 · n=53522024: P95 · n=65882022 2024
Improving position over 2022-2024 · n=3688-6588
Net result P90
2022: P68 · n=36862023: P91 · n=53512024: P90 · n=65822022 2024
Improving position over 2022-2024 · n=3686-6582
Equity P92
2022: P55 · n=36882023: P83 · n=53542024: P92 · n=65882022 2024
Improving position over 2022-2024 · n=3688-6588
Gross operating margin P86
2022: P60 · n=36842023: P86 · n=53482024: P86 · n=65902022 2024
Improving position over 2022-2024 · n=3684-6590
Describes the position versus peers, not a forecast.
EBITDA
€208k
+15.4% 22-24
Net profit
€162k
+15.6% 22-24
Cash flow
€164k
+15.5% 22-24
Total assets
€370k
+68.4% 22-24
Equity
€370k
+78.1% 22-24
Working capital
€203k
+225.7% 22-24
Income taxes
€49k
+19.6% 22-24
Dividends
€800
0.0% 22-24
Show 9 other metrics
Debt
€12k
-31.0% 22-24
Debt ≤ 1y
€12k
-31.0% 22-24
Current ratio
17.88
+290.7% 22-24
Quick ratio
17.88
+290.7% 22-24
Solvency
100.0%
+5.8% 22-24
Debt / equity
0.06
-77.3% 22-24
ROE
43.9%
-35.1% 22-24
ROA
43.9%
-31.3% 22-24
Interest coverage
4655.78
+0.5% 22-24
Figures by fiscal year
Fiscal year2024
Depositmicro
Revenue-
EBITDA€208k
Net profit€162k
Cash flow€164k
Staff costs-
Income taxes€49k
Dividends-
Total assets€370k
Equity€370k
Debt-
of which ≤ 1y-
of which > 1y-
Working capital-
Employees (FTE)-
Ratios (computed)
2024
Current ratio-
Quick ratio-
Working capital ratio-
Solvency100.0%
Debt / equity-
Long-term debt ratio-
Interest coverage4655.78
Gross margin-
Net margin-
ROA43.9%
ROE43.9%
EBITDA margin-
Days sales outstanding-
Days payable outstanding-
Inventory turnover-
Days inventory (DSI)-
Balance-sheet composition 2024
Full annual accounts (18 line items)
Filed balance sheet and income statement, exactly as deposited with the NBB.
Line item Code2024
Balance sheet, Assets
TOTAL ASSETS 20/58€370k
Fixed assets 21/28€3k
Tangible fixed assets 22/27€3k
Current assets 29/58€367k
Amounts receivable within one year 40/41€67k
Cash & bank 54/58€300k
Balance sheet, Equity & liabilities
TOTAL EQUITY & LIABILITIES 10/49€370k
Equity 10/15€370k
Contributions / capital 10/11€4k
Reserves 13€366k
Income statement
Gross operating margin 9900€209k
Operating result 9901€207k
Financial income 75€4k
Financial charges 65€45
Result before taxes 9903€211k
Income taxes 67/77€49k
Net result for the period 9904€162k
Result to be appropriated 9905€162k
This table shows the latest fiscal year. 2 prior years, with figures and ratios, belong to a paid plan. See plans →
Ratios computed by Checked.

Health barometer

FY 2024 · computed
76 / 100 Excellent
050100
Computed from 4 of the 6 factors this model weighs. The rest cannot be derived from the filed figures, or need a prior year to compare against.

The full score breakdown, per-year score history and the indicative credit limit are in Kantoor S.

See plans →
Computed by Checked from the NBB filing for FY 2024. Indicative, not credit advice.

Structure & network

Locations & real estate

Registered office

on the map · from the address register
exact location from the address register On OpenStreetMap

Establishment units

1 location
Dr. Eline Daelemans
Grote Steenweg 17, 9930 LievegemActiviteiten van huisartspraktijken
since 20222.333.148.126
Physical sites registered in the Crossroads Bank for Enterprises (CBE).
Parcels1
Ground area932 m²
Buildings1
Building footprint247 m²
Volume (LiDAR)1,062 m³
Tallest building6.6 m · ±1 fl.

Real-estate footprint

Source: CBE × cadastre · address linking

Parcels linked to this company through its CBE addresses (seat, establishment units, branches), cross-referenced with the cadastral parcel plan. This shows where the company operates, not a deeds register.

Flanders 1 (100%)
Parcel (capakey) Region Area Buildings Height / fl.
44080B1002/00F000 Flanders 932 m² 1 · 247 m² 6.5 m · 1 fl.
Methodology
via registered seat: 1
1 of 1 parcels with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.

Publications

Lifecycle & Insolvency Signals

No insolvency signals in the Belgian State Gazette

Belgian State Gazette · acts

0 of 1 acts read

We know of 1 Belgian State Gazette act for this company. It has not been read yet: what they contain is neither established nor disproved here.

Have them read with priority Sign in to place this company at the front of the reading queue.

The insolvency signals above come from a separate source; the KBO register is the second source and appears as the legal situation on this page.

Analysis

Financial profile

5 of 5 axes measured
Health76Profitability100Solvency100Growth78Stability94
90 / 100

Exceptional profile, strong across almost every axis.

All 5 axes are computed from data Checked has read.

Health 76
Profitability 100
Solvency 100
Growth 78
Stability 94

Credit advice

verdict per customer and amount

May this customer buy amount X on invoice? Enter the amount and the payment term. This page computes a GREEN, AMBER or RED verdict from them, with a suggested ceiling and concrete conditions.

Based on official sources (NBB, CBE, State Gazette). Indicative, not credit advice.

Similar

Similar companies

Comparable size, same sector

Company registry

Company registry (CBE)

Crossroads Bank
Activities
Activiteiten van huisartspraktijken86210
Primary activity highlighted.
Names & trade names
Legal nameNL Dr. Eline Daelemans
Registered office
Grote Steenweg 17
9930 Lievegem, Belgium
Official data from the Crossroads Bank for Enterprises (CBE). Available for every registered company.